Completeness of reporting of randomised controlled trials including people with transient ischaemic attack or stroke: A systematic review

Blair Wilson1, Peter Burnett2, David Moher3, Douglas G Altman4 and Rustam Al-Shahi Salman5

Abstract

Purpose: To assess the adherence of stroke randomised controlled trials to Consolidated Standards Of Reporting Trials reporting guidelines and investigate the factors that are associated with completeness of reporting.

Method: We took a random sample from the Cochrane Stroke Group’s Trial Register of transient ischaemic attack or stroke randomised controlled trials, published in English in 1997–2016 inclusive. Two reviewers assessed the published report of the final primary results of stroke randomised controlled trials with a 10-point truncated Consolidated Standards Of Reporting Trials reporting checklist to investigate adherence over time, univariable associations and independent associations with total Consolidated Standards Of Reporting Trials reporting score in a multiple linear regression model.

Findings: In this random sample of 177 stroke randomised controlled trials, the mean score on the truncated Consolidated Standards Of Reporting Trials checklist was 5.8 (SD 2.2); reporting improved from 1997–2000 (4.9 SD 2.0) to 2001–2009 (5.8 SD 2.1) and to 2010–2016 (6.8 SD 2.1). A higher Consolidated Standards Of Reporting Trials score was independently associated with publication during epochs following a revision of Consolidated Standards Of Reporting Trials reporting guidelines (p < 0.001), journal endorsement of the Consolidated Standards Of Reporting Trials reporting guideline at the time of randomised controlled trial publication (p < 0.001) and modified journal impact factor using median citation distribution (p = 0.012).

Discussion: Stroke randomised controlled trial reporting to Consolidated Standards Of Reporting Trials standards has improved over time, but could be better.

Conclusion: Journal endorsement and enforcement of Consolidated Standards Of Reporting Trials reporting guidelines could further improve the reporting of stroke randomised controlled trials.

Systematic review registration: Registered with PROSPERO (CRD42017072193).

Keywords

Stroke, reporting, Consolidated Standards Of Reporting Trials, randomised controlled trial

Introduction

Randomised controlled trials (RCTs) are the fairest tests of treatment, but judgements about their value are dependent on transparent and complete reporting. Inadequate reporting prevents a complete assessment of an RCT’s risk of bias and description of their results, which can also preclude the re-use of data in meta-analyses.1,2 In order to combat this, the Consolidated Standards Of Reporting Trials (CONSORT) Statement...
was developed in 1996,\textsuperscript{3} updated in 2001\textsuperscript{4} and revised in 2010\textsuperscript{5} to improve the reporting of RCTs. The CONSORT guidelines seem to have been endorsed by over 600 journals.\textsuperscript{6}

In general, studies of RCT reporting have not only demonstrated incomplete reporting in numerous specialties but also modest improvements over time that were often associated with journal endorsement and uptake of CONSORT.\textsuperscript{7–20} Concerns about completeness of reporting remain, particularly in journals with low impact factors.\textsuperscript{7,21}

Despite advances in the prevention and treatment of stroke supported by RCTs, stroke remains the leading cause of disability and second leading cause of death worldwide and stroke burden is projected to increase with changes in lifestyle and longevity.\textsuperscript{22,23} The limited funding available for stroke research to lessen this burden should not be wasted.\textsuperscript{24,25} But concerns remain about waste in stroke research, including the poor reporting of research.\textsuperscript{26,27}

Other than an investigation of the reporting of a specific intervention for stroke rehabilitation,\textsuperscript{28} the last systematic assessment of stroke RCT reporting pre-dated CONSORT.\textsuperscript{9} That review found that the standard of reporting was poor, but it improved over time alongside an increase in RCT sample size. Reporting did not appear to be associated with journal impact factor but trials with a positive outcome tended to be less well reported than those with neutral or negative outcomes.\textsuperscript{9} This differs from the findings in other specialties.\textsuperscript{14,15} However, it is unclear whether stroke RCT reporting has improved since CONSORT guidelines were released and updated, what factors are associated with better reporting, and whether these associations differ from other diseases.\textsuperscript{27}

Therefore, we aimed to assess: the extent to which the published reports of the final primary results of RCTs involving participants with transient ischaemic attack (TIA) or stroke have adhered to the CONSORT reporting guidelines between 1997 and 2016; whether adherence has changed over time, in particular following each revision of the CONSORT guidelines; and which factors are associated with better reporting.

**Methods**

**Protocol and registration**

All authors developed and approved the protocol, which we registered with PROSPERO before embarking on data collection (CRD42017072193).

**Eligibility criteria**

We included published reports of the final primary results of RCTs including patients with TIA or stroke, published in 1997–2016 inclusive. We applied eligibility criteria designed to obtain a representative sample of RCTs (Table 1).

**Information sources**

On 30 August 2017, the Managing Editor of the Cochrane Stroke Group searched the Cochrane Stroke Group’s Trial Register for all publications of RCTs including patients with TIA or any type of stroke published in 1997–2016 inclusive. We used a random number generator in Microsoft Excel to take a random sample of equal size from each of these three groups of RCTs, removed duplicate records of the same RCT in order to include only the report of the final primary results of each RCT, and took further random samples as required to achieve our target sample size of 180 RCTs. We chose this sample size so that it would adequately power a multiple regression analysis including 10 covariates based on the likely distribution of CONSORT reporting scores and be feasible for two reviewers to assess in the time available to the research team.

| **Table 1. Eligibility criteria for included studies.** |
|------------------------------------------------------|
| **Inclusion criteria**                                 |
| Published report of the final primary results of an RCT, published in 1997–2016 inclusive |
| English language publication                           |
| Participants included after TIA or any type of stroke  |
| Any type of therapeutic intervention (drug, surgery, device, rehabilitation, etc.) |
| **Exclusion criteria**                                 |
| Reports of interim analyses that preceded the report of the final primary results of an RCT |
| Reports of secondary or long-term follow-up analyses of an RCT |
| Duplicate reports of the final primary results of an RCT |
| Cost-effectiveness and economic studies of an RCT |
| RCTs in which stroke was not the qualifying condition, but the outcome |

RCT: randomised controlled trial.
Data collection

We imported the results of the search into Covidence (www.covidence.org). One reviewer (BW) screened the titles and abstracts of all RCTs to exclude any ineligible RCTs. Two reviewers (PB and BW) reviewed the full text of potentially eligible RCTs, independent of each other. PB and BW used the data collection tool within Covidence to independently assess the completeness of reporting of included RCTs. Any protocols that were referenced within the included papers were checked and included in the scoring. PB and BW used Microsoft Excel to extract information from each RCT on pre-specified covariates that we hypothesised might be associated with completeness of reporting. Any uncertainties or disagreements about eligibility, completeness of reporting, or covariates were resolved by discussion with another reviewer (RA-SS).

Data items

Our primary outcome was a truncated version of the CONSORT checklist comprising the 10 most important CONSORT checklist items, identified by a group of experts from within the CONSORT group, based on their professional opinion and supported by empirical evidence where available (Table 2). We tackled the problem of partial reporting by adapting the wording of some criteria so that each item could be scored 1 if it was reported or 0 if it was not reported, for a total score ranging from 0 to 10.

In our protocol, we specified the following covariates to investigate associations with completeness of reporting based on prior evidence of their association with completeness of reporting in other diseases: (1) CONSORT endorsement by the journal preceding the publication of the RCT (we established this by searching the CONSORT database online, contacting the journal or searching the journal’s archived guidelines);11–13,20 (2) year of publication;7–10 (3) sample size of the RCT;8,9,14,21 (4) number of recruiting sites (single vs. multicentre);8,9,14,21 (5) direction and statistical significance of results with reference to aims/hypothesis (positive, neutral or negative);9,14,15 (6) type of intervention (drug, surgical or other);15,21 (7) funding source (academic/governmental/charitable vs. commercial vs. other)14,21 and (8) journal impact factor.7,8,21 However, we did not use journal impact factor because it is widely acknowledged to be a flawed metric as it is the arithmetic mean of a highly skewed distribution of citations and it is quoted to a higher level of precision (three decimal places) than is warranted by the underlying data,31 and hence we used a ‘modified journal impact factor’ that uses the median – rather than the mean – number of citations.32 We also pre-specified (9) TIA/stroke type and (10) intervention type (acute, prevention, rehabilitation), which we hypothesised might influence the completeness of reporting of stroke RCTs.

Risk of bias

We reduced bias in our assessments of completeness of reporting and covariates of interest by two reviewers.
assessing them independently. We looked for evidence of differences between reviewers, which might be systematic, by calculating the kappa statistic to assess the inter-reviewer variability for each CONSORT checklist item (Table 2).

**Summary measure**

We used the truncated CONSORT score, which was the sum of the score of each of the 10 fields in the truncated list (Table 2) as our summary measure.

**Statistical analysis**

We assessed trends in trial characteristics with time using the Cochran–Armitage test for trend. We quantified the mean and SD of the truncated CONSORT score. We assessed associations of categorical covariates with truncated CONSORT score using ANOVA and univariable associations with continuous variables using Spearman’s rank-order correlation. We assessed trends in reporting of individual CONSORT items with time using the Cochran–Armitage test for trend. We entered all 10 covariates into a single multiple linear regression model to investigate the association of each of our covariates with total truncated CONSORT score, after checking linearity of relationships, multivariable normality, multi-collinearity, the absence of auto-correlation and homoscedasticity. We used IBM SPSS 24, with \( \alpha = 0.05 \).

**Results**

**Study selection**

From 7813 studies in the Cochrane Stroke Group Trial Register published in 1997–2016 inclusive, we randomly sampled 180 that appeared eligible and included 177 (Figure 1).

**Characteristics of the included RCTs**

The RCTs included a variety of combinations of TIA or stroke sub-types, the most frequent being ischaemic stroke alone (Table 3). Three-quarters of RCTs evaluated acute interventions and almost two-thirds of the interventions were drugs. Sample sizes ranged from 8 to 21,106 patients, median 99 (inter-quartile range 41–367). Roughly half of included RCTs reported statistically significant beneficial (i.e. ‘positive’) effects on

---

**Figure 1.** PRISMA flow chart.
their primary outcomes. Roughly one-fifth of included RCTs received commercial funding. More than one-third of the journals had not explicitly endorsed the CONSORT statement to require complete RCT reporting to the CONSORT standard. There was a statistically significant downward trend in the proportion of acute trials ($p < 0.001$), those investigating a pharmacological intervention ($p = 0.002$) and journals endorsing CONSORT ($p = 0.014$) over time (the latter due to an increase in the number of open access journals in recent times).

### Inter-reviewer agreement

For all 10 items in the truncated CONSORT checklist, inter-reviewer agreement was high, ranging from $\kappa = 0.96$ to $1.00$ for individual items (online appendix).

### Completeness of reporting

In all 177 RCTs, the mean total truncated CONSORT score was 5.8 (SD 2.2) out of 10, (ranging from 1 to 10 in individual RCTs). Completeness of reporting of each

---

### Table 3. Descriptive characteristics of included RCTs.

| Type of TIA/stroke included | All 177 RCTs (%) | 1997–2000, n = 59 (%) | 2001–2009, n = 59 (%) | 2010–2016, n = 59 (%) |
|-----------------------------|------------------|---------------------|---------------------|---------------------|
|Any type                     | 3 (2)            | 3 (5)               | 0 (0)               | 0 (0)               |
|Intracerebral haemorrhage    | 20 (11)          | 5 (8)               | 6 (10)              | 7 (12)              |
|Ischaemic stroke             | 84 (48)          | 30 (51)             | 29 (49)             | 25 (42)             |
|Sub-arachnoid haemorrhage    | 46 (26)          | 16 (27)             | 15 (25)             | 15 (25)             |
|TIA                          | 6 (3)            | 0 (0)               | 1 (2)               | 6 (10)              |
|TIA or ischaemic stroke      | 12 (7)           | 3 (5)               | 6 (10)              | 3 (5)               |
|Unknown                      | 5 (3)            | 2 (3)               | 1 (2)               | 2 (3)               |

| Type of RCT                  |                  |                     |                     |                     |
|Acute                        | 131 (74)         | 53 (90)             | 45 (76)             | 35 (59)             |
|Prevention                   | 10 (6)           | 0 (0)               | 2 (3)               | 8 (14)              |
|Rehabilitation               | 32 (18)          | 6 (10)              | 10 (17)             | 16 (27)             |
|Other                        | 4 (2)            | 0 (0)               | 2 (3)               | 0 (0)               |

| Type of intervention        |                  |                     |                     |                     |
|Drug                         | 112 (63)         | 47 (80)             | 34 (58)             | 31 (53)             |
|Surgical                     | 44 (25)          | 6 (10)              | 10 (17)             | 5 (8)               |
|Other                        | 21 (12)          | 6 (10)              | 15 (25)             | 23 (39)             |

| Number of recruiting sites  |                  |                     |                     |                     |
|Multicentre                  | 87 (49)          | 32 (54)             | 26 (44)             | 29 (49)             |
|Single centre                | 82 (46)          | 25 (42)             | 30 (51)             | 27 (46)             |
|Unknown                      | 8 (5)            | 2 (3)               | 3 (5)               | 3 (5)               |

| Sample size                 |                  |                     |                     |                     |
|Median (IQR)                | 99 (41–367)       | 142 (32–407)        | 90 (40–365)         | 94 (50–233)         |

| RCT outcome                 |                  |                     |                     |                     |
|Positive ($p < 0.05$)        | 92 (52)          | 26 (44)             | 28 (47)             | 27 (46)             |
|Neutral                      | 78 (44)          | 30 (51)             | 27 (46)             | 30 (51)             |
|Negative                     | 7 (4)            | 2 (3)               | 4 (7)               | 2 (3)               |

| Funding source              |                  |                     |                     |                     |
|Not specified                | 66 (37)          | 24 (41)             | 26 (44)             | 16 (27)             |
|Commercial                   | 35 (20)          | 16 (27)             | 11 (19)             | 8 (14)              |
|Other                        | 76 (43)          | 19 (32)             | 22 (37)             | 35 (59)             |

| Journal endorsed CONSORT   |                  |                     |                     |                     |
|Endorsed                    | 108 (61)         | 43 (73)             | 35 (59)             | 30 (51)             |

| Impact factor               |                  |                     |                     |                     |
|Median (IQR)                | 4.2 (2.0–6.0)     | 4.8 (1.4–6.0)       | 5.2 (2.1–5.9)       | 3.0 (2.0–6.2)       |

| Modified impact factora,b  |                  |                     |                     |                     |
|Median (IQR)                | 2 (1–5)          | 2 (1–5)             | 3 (1–5)             | 2 (1–5)             |

TIA: transient ischaemic attack; IQR: inter-quartile range; RCT: randomised controlled trial; CONSORT: Consolidated Standards Of Reporting Trials.

*aItems are reported as frequency (proportion) for categorical variables, unless otherwise specified for continuous variables.

bModified impact factor is the impact factor for the journal at the time of publication calculated using the median rather than mean of the citation distribution.
of the CONSORT items varied considerably (Figure 2). Explicit definitions of the primary outcome measure and the estimated treatment effect size and its precision were most frequently reported and did not decrease over time. Details of trial registration and the availability of the protocol were least frequently reported, but like many other items (other than harms and funding) there was a statistically significant trend of increasing completeness of reporting individual items over time.

**Associations with completeness of reporting**

In univariable analyses, there was a significant improvement in total CONSORT score by 1.9 (95% Confidence Interval (CI) 1.0–2.8) from 1997–2000 until 2010–2016 ($p < 0.001$) and by 1.1 (95% CI 0.2–2.0) from 2001–2009 until 2010–2016 ($p = 0.013$) (Table 4 and Figure 3). Journal endorsement of CONSORT at the time of an RCT’s publication, higher modified journal impact factor, having a commercial funding source, multicentre recruitment and larger sample size were all associated with higher total CONSORT reporting scores (Table 4). In multivariable analysis, publication during epochs following a revision of CONSORT reporting guidelines was independently associated with higher completeness of reporting (Table 5), as was journal endorsement of the CONSORT reporting guideline at the time of RCT publication, and journal modified impact factor.

**Discussion**

In this systematic review of 177 stroke RCTs published over a 20-year period, we found that stroke RCTs on average have reported ~6 out of 10 items on a truncated CONSORT checklist (Figure 2). Encouragingly, the overall completeness of reporting has increased with time such that stroke RCTs published after the 2010 revision of CONSORT reported ~7 out of 10 items (Table 4). This improvement may reflect, at least in part, the awareness or endorsement of CONSORT guidelines by the International Committee of Medical Journal Editors in 2001 and individual journals since then.

The reporting of primary outcomes and estimates of treatment effect on these outcomes have been consistently good, while the least well-reported items were the method of allocation concealment, trial registration and protocol location (Figure 2), perhaps because repositories for the latter two were not available in the earlier epochs in this study. This is similar to findings for trials in other diseases, although the proportion of stroke RCTs adequately reporting registration and the location of protocol is particularly low. Each item that was poorly reported in 1997–2000, excluding harms and funding, has shown an improvement in completeness of reporting with time. The reporting of harms appears to have decreased over time, although this might be confounded by the decrease in the proportion of stroke RCTs investigating drug or surgical interventions over time (Table 3), in which the reporting of harms is more of a requirement than for other interventions (e.g. rehabilitation).

We did not find that the type of intervention was associated with completeness of reporting in stroke RCTs in contrast to previous studies in other subspecialties. The development and implementation of extensions to the CONSORT statement, addressing the
Table 4. Univariable analyses of associations with truncated CONSORT score.

| Categorical covariates                        | Number of RCTs | Mean total CONSORT score (standard deviation) | p     |
|-----------------------------------------------|----------------|-----------------------------------------------|-------|
| Year of publication                          |                |                                               |       |
| 1997–2000                                     | 59             | 4.9 (2.0)                                     | <0.001|
| 2001–2009                                     | 59             | 5.8 (2.1)                                     |       |
| 2010–2016                                     | 59             | 6.8 (2.1)                                     |       |
| TIA/stroke type                               |                |                                               |       |
| Haemorrhagic (ICH or SAH)                    | 66             | 6.1 (2.1)                                     | 0.28  |
| Ischaemic (all other groups)                 | 111            | 5.7 (2.3)                                     |       |
| Trial type                                    |                |                                               |       |
| Acute                                         | 46             | 5.4 (2.3)                                     | 0.11  |
| Other                                         | 131            | 6.0 (2.1)                                     |       |
| Type of intervention                          |                |                                               |       |
| Drug                                          | 112            | 6.0 (2.2)                                     | 0.30  |
| Other                                         | 65             | 5.6 (2.3)                                     |       |
| Number of recruiting sites                    |                |                                               | <0.001|
| Multicentre                                   | 87             | 6.6 (2.0)                                     |       |
| Single centre/not specified                   | 90             | 5.1 (2.1)                                     |       |
| Outcome estimate                              |                |                                               |       |
| Positive                                      | 92             | 5.7 (2.3)                                     | 0.43  |
| Negative or neutral                           | 85             | 6.0 (2.1)                                     |       |
| Funding source                                |                |                                               |       |
| Purely commercial                             | 35             | 6.6 (1.7)                                     | 0.022 |
| Other/not specified                           | 142            | 5.7 (2.3)                                     |       |
| Journal endorsed CONSORT                      |                |                                               | <0.001|
| Endorsed                                      | 108            | 6.6 (2.0)                                     |       |
| Not endorsed                                  | 69             | 4.7 (2.0)                                     |       |

| Continuous covariates                        | Spearman rank-order coefficient | p     |
|-----------------------------------------------|----------------------------------|-------|
| Modified impact factor                        | $r_s = 0.51$                     | <0.001|
| Sample size                                   | $r_s = 0.38$                     | <0.001|

RCTs: randomised controlled trials; CONSORT: Consolidated Standards Of Reporting Trials.

*Haemorrhagic sub-category included intracerebral haemorrhage and subarachnoid haemorrhage, ischaemic encompassed all other sub-categories as this was the most common sub-type within them.

Figure 3. Distribution of CONSORT Scores by Epoch.
weaknesses in reporting of non-drug interventions, may be responsible for this difference.\textsuperscript{33} Similar to the results of others, this study has shown that the time period of publication,\textsuperscript{7–10,14,15} journal endorsement of CONSORT at the time of publication,\textsuperscript{11–13,20} and multicentre recruitment\textsuperscript{21} are all independently associated with a higher completeness of reporting in stroke RCTs. Others have also identified commercial funding as being associated with better completeness of reporting.\textsuperscript{4,34,35} Our study used a modified journal impact factor, which was associated with a higher total CONSORT checklist score. This finding is in agreement with those of recent studies,\textsuperscript{7,8,21} but in contrast to the earlier stroke RCT study.\textsuperscript{9} We speculate that this could be explained by the increased scrutiny and stricter peer-review processes implemented by higher impact journals in recent years, influenced by the drive to improve completeness of reporting nowadays.\textsuperscript{2}

Our study differs from the results of the only previous study of the completeness of reporting of stroke RCTs, which found that completeness of reporting was associated with estimates of treatment effect.\textsuperscript{9}

As far as we are aware this is the only study to assess completeness of reporting and the associated factors for stroke RCTs in the 21st century. However, it is not without its weaknesses. We scored RCTs using a modified, truncated CONSORT checklist, to give a score out of 10 as a measure of completeness of reporting of key items. Each of the factors was weighted equally, but these factors vary in their importance; however, any attempt to implement a weighted system to this list would be arbitrary and introduce a degree of subjectivity which would limit the generalisability of our results. An advantage of this binary scoring system was the high inter-reviewer agreement in the assessment of reporting. Other scoring systems are

### Table 5. Multivariable linear regression analysis of associations with truncated CONSORT score.

|                      | RCTs (n) | Mean CONSORT score (SD) | Multiple linear regression |   |
|----------------------|----------|-------------------------|---------------------------|---|
|                      |          |                         | /\ Coefficient 95% CI p    |   |
| Year of publication  |          |                         |                           |   |
| 1997–2000            | 59       | 4.9 (2.0)               | Ref                       |   |
| 2001–2009            | 59       | 5.8 (2.1)               | 1.071 0.435 to 1.709 0.001|   |
| 2010–2016            | 59       | 6.8 (2.1)               | 2.248 1.559 to 2.937 <0.001|   |
| TIA/stroke type\textsuperscript{a} |          |                         |                           |   |
| Haemorrhagic         | 66       | 6.1 (2.1)               | Ref                       |   |
| Ischaemic            | 111      | 5.7 (2.3)               | -0.204 -0.794 to 0.387 0.497|   |
| Trial type           |          |                         |                           |   |
| Other                | 131      |                         | Ref                       |   |
| Acute                | 46       |                         | 0.118 -0.626 to 0.863 0.754|   |
| Type of intervention |          |                         |                           |   |
| Other                | 65       | 5.4 (2.3)               | Ref                       |   |
| Drug                 | 112      | 6.0 (2.1)               | 0.098 -0.505 to 0.702 0.748|   |
| Number of recruiting sites |          |                         |                           |   |
| Other                | 90       | 6.6 (2.0)               | Ref                       |   |
| Multicentre          | 87       | 5.1 (2.1)               | 0.672 0.132 to 1.211 0.015|   |
| Sample size          |          |                         |                           |   |
| Per n=100 increase   | 177      |                         | 0.009 -0.001 to 0.019 0.066|   |
| Outcome estimate     |          |                         |                           |   |
| Negative or neutral  | 85       | 5.7 (2.3)               | Ref                       |   |
| Positive             | 92       | 6.0 (2.1)               | -0.216 -0.722 to 0.290 0.400|   |
| Funding source       |          |                         |                           |   |
| Other                | 142      | 6.6 (1.7)               | Ref                       |   |
| Purely commercial    | 35       | 5.7 (2.3)               | 0.543 -0.127 to 1.212 0.112|   |
| Journal endorsed CONSORT |          |                         |                           |   |
| Not endorsed         | 69       | 6.6 (2.0)               | Ref                       |   |
| Endorsed             | 108      | 4.7 (2.0)               | 1.382 0.726 to 2.038 <0.001|   |
| Modified impact factor |          |                         |                           |   |
| For each unit increase | 177     |                         | 0.127 0.028 to 0.226 0.012|   |

RCTs: randomised controlled trials; CONSORT: Consolidated Standards Of Reporting Trials.

Multiple linear regression model adjusted for year of publication, TIA/stroke type, trial type, type of intervention, number of recruiting sites, sample size, outcome estimate, funding source, CONSORT endorsement and modified impact factor. ‘Ref’ indicates which categories were used as reference categories in the multiple linear regression.
subject to lower and more variable kappa values, e.g. ranging from 0.02 to 0.92. Lastly, some of our findings may be confounded by factors relating to publication culture: we found that lower impact factor journals exhibited poorer reporting of RCTs, possibly reflecting the fact that higher quality stroke RCTs may be first submitted to higher impact factor journals.

In summary, the standard of reporting of stroke RCTs has improved with time, but there is room for improvement, particularly in lower impact factor journals. This study provides evidence for areas which can be improved. Authors of stroke RCTs should focus on better reporting of the method of allocation concealment, trial registration and protocol availability. The independent associations that we found between journal-level covariates and completeness of stroke RCT reporting suggest that journals may be best placed to improve reporting completeness by endorsement and enforcement of the CONSORT checklist. One study, but not all, shows that making adherence to CONSORT guidelines mandatory improves completeness of reporting. We therefore suggest that journals require the submission of a completed CONSORT checklist with stroke RCT manuscripts, and that this becomes an integrated part of the peer-review assessment. This may help make reporting standards uniform across journals, and therefore rectify the disparity between journals of high- and low-impact factors. Continuous monitoring of reporting completeness and other sources of research waste will be necessary and can be done by researchers in collaboration with the REWARD Alliance (http://rewardalliance.net).

Declaration of Conflicting Interests
The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: DM and DGA helped to develop the CONSORT Statement; they are members of the CONSORT executive. DM and RA-SS are also members of the REWARD alliance.

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

Informed consent
Not applicable.

Ethical approval
Not applicable.

Guarantor
RAAS.

Contributorship
All authors were involved with the planning and design of the study. BW and PB carried out the study. BW wrote the manuscript which was edited and revised by all authors.

Acknowledgements
We dedicate this article to Doug Altman (12 July 1948 – 3 June 2018), for inspiring us to improve the reliability and reporting of randomised trials. We are very grateful to Hazel Fraser, the Managing Editor of the Cochrane Stroke Group, and all the members who facilitated the database search and helped us obtain full manuscripts of selected articles.

References
1. Chan A-W, Song F, Vickers A, et al. Increasing value and reducing waste: addressing inaccessible research. Lancet 2014; 383: 257–266.
2. Glasziou P, Altman DG, Bossuyt P, et al. Reducing waste from incomplete or unusable reports of biomedical research. Lancet 2014; 383: 267–276.
3. Begg C, Cho M, Eastwood S, et al. Improving the quality of reporting of randomized controlled trials: the CONSORT statement. JAMA 1996; 276: 637–639.
4. Moher D, Schulz KF and Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001; 357: 1191–1194.
5. Schulz KF, Altman DG and Moher D. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010; 34: c332.
6. Shamseer L, Hopewell S, Altman DG, et al. Update on the endorsement of CONSORT by high impact factor journals: a survey of journal “Instructions to Authors” in 2014. Trials 2016; 17: 301.
7. Dechartres A, Trinquart L, Atal I, et al. Evolution of poor reporting and inadequate methods over time in 20 920 randomised controlled trials included in Cochrane reviews: research on research study. BMJ 2017; 357: j2490.
8. Arra I, Velker V, Sexton T, et al. A CONSORT clinical trial reporting compliance audit of the oncology randomised controlled trial literature. Cureus 2013; 5: e104.
9. Bath FJ, Owen VE and Bath PM. Quality of full and final publications reporting acute stroke trials. Stroke 1998; 29: 2203–2210.
10. Thoma A, Chew RT, Sprague S, et al. Application of the CONSORT statement to randomized controlled trials comparing endoscopic and open carpal tunnel release. Can J Plast Surg 2006; 14: 205–210.
11. Plint AC, Moher D, Morrison A, et al. Does the CONSORT checklist improve the quality of reports of randomised controlled trials? A systematic review. Med J Aust 2006; 185: 263.
12. Devereaux P, Manns BJ, Ghali WA, et al. The reporting of methodological factors in randomized controlled trials and the association with a journal policy to promote adherence to the Consolidated Standards of Reporting
Trials (CONSORT) checklist. Control Clin Trials 2002; 23: 380–388.

13. Turner L, Shamseer L, Altman DG, et al. Does use of the CONSORT Statement impact the completeness of reporting of randomised controlled trials published in medical journals? A Cochrane review. Syst Rev 2012; 1: 60.

14. Farrokhyar F, Chu R, Whitlock R, et al. A systematic review of the quality of publications reporting coronary artery bypass grafting trials. Can J Surg 2007; 50: 266.

15. Thabane L, Chu R, Cuddy K, et al. What is the quality of reporting in weight loss intervention studies? A systematic review of randomized controlled trials. Int J Obes 2007; 31: 1554.

16. Bhandari M, Guyatt GH, Lochner H, et al. Application of the consolidated standards of reporting trials (CONSORT) in the fracture care literature. JBJS 2002; 84: 485–489.

17. Jacquier I, Boutron I, Moher D, et al. The reporting of randomized clinical trials using a surgical intervention is in need of immediate improvement. A systematic review. Ann Surg 2006; 244: 677.

18. Latronico N, Botteri M, Minelli C, et al. Quality of reporting of randomised controlled trials in the intensive care literature. Intensive Care Med 2002; 28: 1316–1323.

19. Gluud C and Nikolova D. Quality assessment of reports on clinical trials. J Hepatol 1998; 29: 321–327.

20. Turner L, Shamseer L, Altman DG, et al. Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals. Cochrane Database Syst Rev 2012; 11. Art. No.: MR000030. DOI: 10.1002/14651858.MR000030.pub2

21. Balasubramanian SP, Wiener M, Alshameeri Z, et al. Standards of reporting of randomized controlled trials in general surgery: can we do better?. Ann Surg 2006; 244: 663.

22. WHO. The top 10 causes of death. http://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death (accessed 3 June 2018)

23. Krishnamurthi RV, Feigin VL, Forouzanfar MH, et al. Global and regional burden of first-ever ischaemic and haemorrhagic stroke during 1990–2010: findings from the Global Burden of Disease Study 2010. Lancet Glob Health 2013; 1: e259–e281.

24. Luengo-Fernandez R, Leal J and Gray A. UK research spend in 2008 and 2012: comparing stroke, cancer, coronary heart disease and dementia. BMJ Open 2015; 5: e006648.

25. Pendlebury ST. Worldwide under-funding of stroke research. Int J Stroke 2007; 2: 80–84.

26. Chalmers I and Glasziou P. Avoidable waste in the production and reporting of research evidence. Obstet Gynecol 2009; 114: 1341–1345.

27. Berge E, Al-Shahi Salman R, van der Worp HB, et al. Increasing value and reducing waste in stroke research. Lancet Neurol 2017; 16: 399–408.

28. Zeng J, Lin G, Li L, et al. Assessment of reporting quality in randomised controlled trials of acupuncture for post-stroke rehabilitation using the CONSORT statement and STRICTA guidelines. Acupunct Med 2017; 35: 100–106.

29. Moher D, Schulz KF and Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomized trials. BMC Med Res Methodol 2001; 1: 2.

30. Hopewell S, Boutron I, Altman DG, et al. Impact of a web-based tool (WebCONSORT) to improve the reporting of randomised trials: results of a randomised controlled trial. BMC Med 2016; 14: 199.

31. Seglen PO. Why the impact factor of journals should not be used for evaluating research. BMJ 1997; 314: 498.

32. Lariviere V, Kiermer V, MacCallum CJ, et al. A simple proposal for the publication of journal citation distributions. Biorxiv 2016; 062109; DOI: 10.1101/062109.

33. Boutron I, Altman DG, Moher D, et al. CONSORT statement for randomized trials of nonpharmacologic treatments: a 2017 update and a CONSORT extension for nonpharmacologic trial abstracts. Ann Intern Med 2017; 167: 40–47.

34. Djulbegovic B, Lavecic M, Cantor A, et al. The uncertainty principle and industry-sponsored research. Lancet 2000; 356: 635–638.

35. Easterbrook PJ, Gopalan R, Berlin J, et al. Publication bias in clinical research. Lancet 1991; 337: 867–872.

36. Hopewell S, Ravaud P, Baron G, et al. Effect of editors’ implementation of CONSORT guidelines on the reporting of abstracts in high impact medical journals: interrupted time series analysis. BMJ 2012; 344: e4178.